Abstract
Wnt/beta-catenin signaling is constitutively increased in several major classes of tumors arising from the urogenital tract. In this review we focus on this pathway mainly in Wilms tumors and prostate carcinomas, followed by a brief discussion of its potential role in other types of urological tumors. Molecular studies in these types of cancers have highlighted novel components upstream and downstream of this central oncogenic pathway. Beta-catenin gain-of-function mutations are strongly linked to WT1 loss-of-function mutations in syndromic Wilms tumors, and Wnt/beta-catenin signaling increases androgen receptor mRNA expression and blocks apoptosis in prostate cancers. Novel downstream target genes activated by Wnt/beta-catenin signaling are emerging from expression profiling in genetically defined classes of Wilms tumors, and similar analyses are expected to reveal additional downstream genes of this pathway specific to prostate cancers. The identities of these genes will likely suggest new targeted therapies for urological malignancies.
Keywords: Wilms tumor, kidney development, prostate cancer, Wnt, beta-catenin, WT1, androgen receptor, urological tumors
Current Molecular Medicine
Title: The Wnt/Beta-Catenin Pathway in Wilms Tumors and Prostate Cancers
Volume: 7 Issue: 5
Author(s): Benjamin Tycko, Chi-Ming Li and Ralph Buttyan
Affiliation:
Keywords: Wilms tumor, kidney development, prostate cancer, Wnt, beta-catenin, WT1, androgen receptor, urological tumors
Abstract: Wnt/beta-catenin signaling is constitutively increased in several major classes of tumors arising from the urogenital tract. In this review we focus on this pathway mainly in Wilms tumors and prostate carcinomas, followed by a brief discussion of its potential role in other types of urological tumors. Molecular studies in these types of cancers have highlighted novel components upstream and downstream of this central oncogenic pathway. Beta-catenin gain-of-function mutations are strongly linked to WT1 loss-of-function mutations in syndromic Wilms tumors, and Wnt/beta-catenin signaling increases androgen receptor mRNA expression and blocks apoptosis in prostate cancers. Novel downstream target genes activated by Wnt/beta-catenin signaling are emerging from expression profiling in genetically defined classes of Wilms tumors, and similar analyses are expected to reveal additional downstream genes of this pathway specific to prostate cancers. The identities of these genes will likely suggest new targeted therapies for urological malignancies.
Export Options
About this article
Cite this article as:
Benjamin Tycko , Chi-Ming Li and Ralph Buttyan , The Wnt/Beta-Catenin Pathway in Wilms Tumors and Prostate Cancers, Current Molecular Medicine 2007; 7 (5) . https://dx.doi.org/10.2174/156652407781387118
DOI https://dx.doi.org/10.2174/156652407781387118 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design Metallothioneins and Cancer
Current Protein & Peptide Science Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy
Current Molecular Medicine Cancer Therapeutics: Emerging Targets and Trends
Current Cancer Therapy Reviews Players in ADP-ribosylation: Readers and Erasers
Current Protein & Peptide Science Nur77 Family of Nuclear Hormone Receptors
Current Drug Targets - Inflammation & Allergy Non-viral Gene Delivery and Therapeutics Targeting to Brain
Current Nanoscience Vascular Endothelial Growth Factor (VEGF) in the Pathogenesis of Diabetic Nephropathy of Type 1 Diabetes Mellitus
Current Drug Targets Radiosyntheses using Fluorine-18: The Art and Science of Late Stage Fluorination
Current Topics in Medicinal Chemistry Nanoscale Formulations and Diagnostics With Their Recent Trends: A Major Focus of Future Nanotechnology
Current Pharmaceutical Design Rediscovering Tocophersolan: A Renaissance for Nano-Based Drug Delivery and Nanotheranostic Applications
Current Drug Targets Therapeutic Benefits of <i>Piper nigrum</i>: A Review
Current Bioactive Compounds Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions
Current Drug Metabolism Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Retraction Note: Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer
Current Pharmaceutical Biotechnology Central and Peripheral Pain Generators in Women with Chronic Pelvic Pain: Patient Centered Assessment and Treatment
Current Rheumatology Reviews Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Recent Developments of Small Molecule EGFR Inhibitors Based on the Quinazoline Core Scaffolds
Anti-Cancer Agents in Medicinal Chemistry Metabolic Targets of Cardiac HormonesTherapeutic Anti-Cancer Effects
Current Pharmaceutical Design Neuropeptides as Therapeutic Targets in Anxiety Disorders
Current Pharmaceutical Design